Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells
Abstract Hepatocellular carcinoma (HCC) is one of the most common malignancy-related deaths. p53 mutation in HCC associates with worse clinicopathologic features including therapeutic limitation. A combination of targeted therapy may have some advantages. Akt/mTOR signaling contributes to the regula...
Saved in:
Main Authors: | Tapas Patra, Keith Meyer, Ratna B. Ray, Tatsuo Kanda, Ranjit Ray |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/3e23d0b8a3bc45bab032fe4d6ec552a6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
by: Morris E Feldman, et al.
Published: (2009) -
A small molecule inhibitor of Rheb selectively targets mTORC1 signaling
by: Sarah J. Mahoney, et al.
Published: (2018) -
Location-specific inhibition of Akt reveals regulation of mTORC1 activity in the nucleus
by: Xin Zhou, et al.
Published: (2020) -
mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
by: Xiaolei Ding, et al.
Published: (2016) -
mTORC1 and PKB/Akt control the muscle response to denervation by regulating autophagy and HDAC4
by: Perrine Castets, et al.
Published: (2019)